In a new job - March 4, 2020
Scandinavian Biopharma appoints a new researcher
Scandinavian Biopharma announces that Morgan Hjorth has joined their team. Morgan Hjorth recently graduate from Karolinska Institute and Royal Institute of Technology (KTH) with two bachelor’s degrees and one Master degree of Science in Medical Biotechnology Engineering. “It feels great to be a part of Scandinavian Biopharma. It’s really motivating to work with the late […]
Clinical Trials - February 20, 2020
Scandinavian Biopharma secures 10.6 million EUR
Scandinavian Biopharma has been awarded a 10.6 million EUR grant from EDCTP in international competition for the planned Phase III clinical trial of the ETEC vaccine candidate ETVAX. The EDCTP grant is a part of the European Framework Programme for Research and Innovation, Horizon 2020. Make the vaccine preparation more fieldable and user-friendly The project […]
Agreement - January 28, 2020
Scandinavian Biopharma expands its Nordic vaccine business
Scandinavian Biopharma has entered into a Nordic distribution agreement with Emergent Travel Health for the oral typhoid vaccine Vivotif. Typhoid fever is a severe and potentially life-threatening infection caused by the Salmonella bacteria. Since 1st of January 2020 Scandinavian Biopharma is the local representative for Vivotif in Sweden, Norway, Denmark and Finland. “We are really […]
In a new job - January 7, 2020
She is Scandinavian Biopharma’s new VP Quality Assurance
Scandinavian Biopharma has appointed Christine Källén as VP Quality Assurance. She will supersede Annette Elmqvist, who is retiring at the end of the year. Christine’s career spans over more than 20 years in quality assurance. Most recently Christine worked at the Swedish Nuclear Fuel and Waste Management Company, SKB, where she was the coordinator and […]
Clinical Trials - November 25, 2019
Scandinavian Biopharma reports positive trial results
Scandinavian Biopharma reports successful results of the ETEC vaccine candidate ETVAX in a placebo-controlled phase I/II study in infants and children in Bangladesh. The successful results of the Phase I/II study in Dhaka, Bangladesh, are now published in The Lancet Infectious Diseases. Safe and broadly immunogenic All predefined primary endpoints for the study were achieved […]
Clinical Trials - October 8, 2019
Scandinavian Biopharma has completed the enrolment of the first cohort in Zambia study
The first cohort of 40 adults was enrolled in the company’s Phase I study in Zambia. The study is part of a late phase development program in Africa funded by EDCTP with 7,4 million Euro. The program consists of two clinical trials and is initiated with a Phase I trial in Zambia to evaluate the […]
